Payment overview · 2025
General Payments
$548.34
31 reported records · 11 companies
Healthcare provider profile · identity verified
Cleatious David Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · JAY, FL · NPI 1871546515
Verified facts
What the public records show
CMS Open Payments records show Cleatious David Smith, MD received $548.34 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.19 | 27.8% | 10 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.44 | 16.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.40 | 15.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.57 | 12.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.68 | 7.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.16 | 4.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.20 | 3.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.46 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.08 | 3.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.71 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.45 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $548.34 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.69 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.31 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.57 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.57 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.68 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
303 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1242 | 236 |
| Gabapentin | Gabapentin | 1040 | 147 |
| Potassium Chloride | Potassium Chloride | 944 | 176 |
| Losartan Potassium | Losartan Potassium | 934 | 193 |
| Omeprazole | Omeprazole | 927 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 897 | 160 |
| Tizanidine Hcl | Tizanidine Hcl | 860 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 799 | 144 |
| Spironolactone | Spironolactone | 772 | 151 |
| Trazodone Hcl | Trazodone Hcl | 727 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 715 | 128 |
| Furosemide | Furosemide | 710 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 709 | 146 |
| Montelukast Sodium | Montelukast Sodium | 644 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 587 | 85 |
| Tramadol Hcl | Tramadol Hcl | 483 | 85 |
| Ropinirole Hcl | Ropinirole Hcl | 427 | 64 |
| Lisinopril | Lisinopril | 423 | 82 |
| Prednisone | Prednisone | 415 | 196 |
| Ezetimibe | Ezetimibe | 403 | 81 |
| Clonidine Hcl | Clonidine Hcl | 402 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 393 | 64 |
| Bupropion Xl | Bupropion Hcl | 386 | 56 |
| Oxybutynin Chloride | Oxybutynin Chloride | 374 | 59 |
| Allopurinol | Allopurinol | 354 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 345 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 341 | 56 |
| Carvedilol | Carvedilol | 331 | 59 |
| Eliquis | Apixaban | 315 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 315 | 60 |
| Pregabalin | Pregabalin | 306 | 55 |
| Farxiga | Dapagliflozin Propanediol | 303 | 42 |
| Clonazepam | Clonazepam | 299 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 278 | 168 |
| Simvastatin | Simvastatin | 277 | 49 |
| Amitriptyline Hcl | Amitriptyline Hcl | 275 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 71 |
| Pioglitazone Hcl | Pioglitazone Hcl | 249 | 49 |
| Celecoxib | Celecoxib | 242 | 43 |
| Metformin Hcl Er | Metformin Hcl | 240 | 58 |
| Famotidine | Famotidine | 228 | 50 |
| Topiramate | Topiramate | 227 | 33 |
| Alendronate Sodium | Alendronate Sodium | 225 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 216 | 36 |
| Memantine Hcl | Memantine Hcl | 210 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 208 | 54 |
| Meloxicam | Meloxicam | 207 | 40 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 205 | 56 |
| Raloxifene Hcl | Raloxifene Hcl | 203 | 39 |
| Januvia | Sitagliptin Phosphate | 194 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 184 | 65 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 174 | 131 |
| Gentamicin Sulfate | Gentamicin Sulfate | 172 | 104 |
| Propranolol Hcl | Propranolol Hcl | 168 | 32 |
| Levofloxacin | Levofloxacin | 167 | 119 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 165 | 31 |
| Bumetanide | Bumetanide | 162 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 157 | 42 |
| Promethazine Hcl | Promethazine Hcl | 152 | 36 |
| Donepezil Hcl | Donepezil Hcl | 151 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 18 |
| Alprazolam | Alprazolam | 150 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 23 |
| Nystatin | Nystatin | 142 | 70 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 140 | 29 |
| Estradiol | Estradiol | 135 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 134 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 134 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 132 | 87 |
| Finasteride | Finasteride | 129 | 30 |
| Naproxen | Naproxen | 129 | 24 |
| Lubiprostone | Lubiprostone | 127 | 24 |
| Glimepiride | Glimepiride | 125 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 124 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 17 |
| Sertraline Hcl | Sertraline Hcl | 119 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 20 |
| Ozempic | Semaglutide | 105 | 18 |
| Sucralfate | Sucralfate | 101 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 22 |
| Doxepin Hcl | Doxepin Hcl | 99 | 23 |
| Hydrocortisone | Hydrocortisone | 97 | 42 |
| Dicyclomine Hcl | Dicyclomine Hcl | 94 | 23 |
| Primidone | Primidone | 93 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 92 | 18 |
| Nitroglycerin | Nitroglycerin | 91 | 48 |
| Metolazone | Metolazone | 89 | 12 |
| Amoxicillin | Amoxicillin | 87 | 62 |
| Linzess | Linaclotide | 86 | 11 |
| Fenofibrate | Fenofibrate | 81 | 20 |
| Xarelto | Rivaroxaban | 81 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 76 | 25 |
| Midodrine Hcl | Midodrine Hcl | 76 | 17 |
| Colestipol Hcl | Colestipol Hcl | 72 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 12 |
| Baclofen | Baclofen | 69 | 14 |
| Digoxin | Digoxin | 66 | 11 |
| Megestrol Acetate | Megestrol Acetate | 64 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 14 |
| Indapamide | Indapamide | 62 | 13 |
| Meclizine Hcl | Meclizine Hcl | 62 | 29 |
| Synthroid | Levothyroxine Sodium | 62 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | suppressed |
| Rybelsus | Semaglutide | 61 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 12 |
| Fluconazole | Fluconazole | 57 | 30 |
| Lorazepam | Lorazepam | 57 | 13 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 14 |
| Ranolazine Er | Ranolazine | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 52 | suppressed |
| Minoxidil | Minoxidil | 51 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 49 | suppressed |
| Methocarbamol | Methocarbamol | 47 | 11 |
| Gemfibrozil | Gemfibrozil | 45 | suppressed |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Imipramine Hcl | Imipramine Hcl | 43 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 20 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 26 |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Klor-Con 10 | Potassium Chloride | 34 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 30 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 17 |
| Temazepam | Temazepam | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 16 |
| Mupirocin | Mupirocin | 26 | 22 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Terconazole | Terconazole | 20 | 14 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Metformin Hcl | Metformin Hcl | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Diazepam | Diazepam | 14 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Tegretol Xr | Carbamazepine | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $548.34 · 31 records | Novo Nordisk Inc | AIRSUPRA, CREON, Dexcom G6 Transmitter, IBSRELA, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error